Ameritas Investment Partners Inc. Decreases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Ameritas Investment Partners Inc. lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,008 shares of the company’s stock after selling 141 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Medpace were worth $2,063,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Rise Advisors LLC purchased a new stake in Medpace in the 1st quarter valued at $27,000. Mather Group LLC. acquired a new position in shares of Medpace during the 1st quarter valued at about $28,000. Fidelis Capital Partners LLC purchased a new stake in shares of Medpace in the first quarter valued at about $31,000. DT Investment Partners LLC acquired a new stake in Medpace during the second quarter worth about $41,000. Finally, J.Safra Asset Management Corp raised its stake in Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 47 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Down 0.9 %

MEDP opened at $365.70 on Friday. The firm has a market cap of $11.33 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 1.74 and a beta of 1.35. The stock’s 50-day moving average price is $378.15 and its 200 day moving average price is $391.95. Medpace Holdings, Inc. has a 12-month low of $227.21 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million during the quarter, compared to analyst estimates of $528.41 million. During the same quarter last year, the firm posted $1.93 earnings per share. The business’s revenue for the quarter was up 14.6% compared to the same quarter last year. On average, research analysts forecast that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. TD Cowen cut their price target on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Guggenheim reduced their target price on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft decreased their price target on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. Mizuho began coverage on Medpace in a research report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price objective for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $420.88.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.